Scott Tarriff - 27 Feb 2024 Form 4 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)

Role
10%+ Owner
Signature
/s/ Scott Tarriff
Issuer symbol
EGRX
Transactions as of
27 Feb 2024
Net transactions value
-$20,312
Form type
4
Filing time
29 Feb 2024, 16:44:24 UTC
Previous filing
09 Jan 2024
Next filing
01 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EGRX Common Stock Award +12,950 +2.9% 465,894 27 Feb 2024 Direct F1, F2
transaction EGRX Common Stock Tax liability $20,312 -3,154 -0.68% $6.44 462,740 27 Feb 2024 Direct F3
holding EGRX Common Stock 992,623 27 Feb 2024 By Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock received upon vesting of performance stock units ("PSUs") that were granted on February 2, 2021.
F2 Reflects the transfer of 88,181 shares of Common Stock pursuant to a Rule 16a-12 transaction.
F3 The disposition reported on this Form 4 represents shares of Common Stock withheld by the Issuer to cover the tax liability upon the vesting of PSUs on February 27, 2024 and does not represent a discretionary transaction by the Reporting Person.
F4 Shares held by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust") for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest, if any, therein.